P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML

Journal:

Science Advances

Published:

2026-05-15

DOI:

10.1126/sciadv.aec9305

Affiliations:

6

Authors:

9

Go to article

Institutions	Authors	Share
Sidney Kimmel Cancer Center (SKCC), TJU, United States of America (USA)	5.000000	0.56
Cellcentric, United Kingdom (UK)	2.000000	0.22
UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC), United States of America (USA)	1.000000	0.11
University of Pennsylvania (Penn), United States of America (USA)	1.000000	0.11

Interested in Oncology and Carcinogenesis?